Clinical Trial Update: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluates low-intensity chemotherapy in combination with ponatinib and blinatumomab for Philadelphia chromosome-positive and BCR-ABL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Accelerated Phase Chronic Myeloid Leukemia Bcr-abl1 Positive
• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia with Bcr-abl1
• Blast Phase Chronic Myeloid Leukemia Bcr-abl1-positive

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• Iclusig (ponatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING